Elan

Elan EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Elan (6099.T) as of Oct 9, 2026 is 12.11. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 10.43 — a change of 16.07% (higher).

EV/FCF

12.11

YoY

16.07%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Elan is 2025 12.11 . EV/FCF (Enterprise Value to Free Cash Flow) of Elan was 2024 10.43 . It decreases by 16.07% higher compared to the previous year.

The Elan EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
38.12 JPY
Jan 1, 2019
57.96 JPY
Jan 1, 2020
21.53 JPY
Jan 1, 2021
19.19 JPY
Jan 1, 2022
31.21 JPY
Jan 1, 2023
24.65 JPY
Jan 1, 2024
10.43 JPY
Jan 1, 2025
12.11 JPY
The Elan EV/FCF history
YEAREV/FCFYoY
12.11+16.07%
10.43-57.68%
24.65-21.04%
31.21+62.64%
19.19-10.87%
21.53-62.84%
57.96+52.02%
38.12-78.10%
174.12+43.97%
120.94-26.12%
163.69-4.90%
172.14—
Access this data via the Eulerpool API

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

EV/FCF (Enterprise Value to Free Cash Flow) of Elan is 12.11 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Elan changed from 10.43 to 12.11, representing a 16.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Elan since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Elan with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Elan

All Key Metrics — Elan